2011 Proceedings
2010 Proceedings
2009 Proceedings
2008 Proceedings
2007 Program
2006 Program
5th Annual Peptide Therapeutics Symposium, October 2010
Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies.
Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies.
John Diekman, Ph.D., Founder & Managing Partner, 5AM Ventures
Shehan Dissanayake, PhD, CEO, Tavistock Life Sciences
Malcolm Finlayson, Ph.D., Venture Partner, Hamilton Bioventures
Pratik Shah, Ph.D., Venture Partner, Thomas, McNerney & Partners
Chemical Synthesis in the Development of Protein Therapeutics by Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago
Chemically Programmed Immunity: Making Peptides Drugs and More by Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute
Tumor-penetrating Peptides in Targeted Tumor Treatment by Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford-Burnham Medical Research Institute
Glioblastoma: Cancer Stem Cells and Reprogramming by Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies
From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy by Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California Davis Cancer Center
Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals by Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory
Early Clinical Development of Novel Biologics by Richard Jones, M.D., Chief Medical Officer, Syntaxin
Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals by Richard Ross, M.D., Chief Scientific Officer and Director, Asterion
Antibody Drug Conjugates: Current and Future Developments by Hans-Peter Gerber, Ph.D., Senior Director Pfizer
Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy by Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics
New Horizons in Protein Medicinal Chemistry Enabled with an Expanded Genetic Code by Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc.
4th Annual Peptide Therapeutics Symposium, November 2009
Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development.
New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD.
NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD.
Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD
Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University.
Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics.
Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals.
Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics.
Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc.
Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.
3rd Annual Peptide Therapeutics Symposium, October 2008
CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX
Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc.
V1a Agonists in Vasodilatory Shock: From Bedside to Bench, and Back by Donald W. Landry, M.D., Ph.D., Chair, Department of Medicine, Columbia University
LAPSCOVERY Technology and Its Application to Long Acting Peptide/Protien Drugs by Gwan Sun Lee, Ph.D., Managing Research Director, Hanmi Research Center, Hanmi Pharm. Co., Ltd
Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation
Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc.
Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development
2nd Annual Peptide Therapeutics Symposium, November 2007
Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals
Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University
Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals
KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute
The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp.
The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals
"Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen
Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London
1st Annual Peptide Therapeutics Symposium, November 2006
Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona
GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana
Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals
Osteoporosis, Regenerating Bone and Parathyroid Hormone by Michael Rosenblatt, Ph.D., Dean, Tufts University Medical School
History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals
Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President & CEO, Cara Therapeutics
Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.